Kidney Nerve Zapper: Hypertension Device Patent Extended
Published Date: 1/27/2026
Notice
Summary
The FDA has officially set the review period for the Symplicity Spyral Renal Denervation System, a medical device used to treat high blood pressure. This means the company can apply to extend its patent, giving them more time to protect their invention and potentially earn more money. If you want to share your thoughts, you have until March 30, 2026, to send in comments.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA Sets 3,161‑Day Review Period
The FDA determined the regulatory review period for the SYMPLICITY SPYRAL RENAL DENERVATION SYSTEM is 3,161 days: 2,801 days in the testing phase and 360 days in the approval phase. That determination lets the patent holder apply to the U.S. Patent and Trademark Office for patent term extension — the applicant seeks 1,491, 1,571, or 1,767 days of extension.
Public Comment and Petition Window
Anyone can submit comments on FDA's determination through https://www.regulations.gov or by mail until 11:59 p.m. Eastern Time on March 30, 2026. Under 21 CFR 60.24 and 21 CFR 60.30, interested persons may ask for a redetermination of the published dates or petition regarding whether the applicant acted with due diligence, and such petitions must be timely and meet the filing requirements described in the notice.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2026-01573 — Determination of Regulatory Review Period for Purposes of Patent Extension; TRYVIO
The FDA has set the official review period for the drug TRYVIO, which helps the company extend its patent protection. This means the drug maker could get extra time to keep exclusive rights, potentially affecting when generic versions can appear. If anyone thinks the dates are wrong or wants to challenge the company’s effort during review, they have until March 30 or July 27, 2026, to speak up.
Next: 2026-01575 — Determination of Regulatory Review Period for Purposes of Patent Extension; IMAAVY
The FDA has officially set the review period for IMAAVY, a human biological product, which helps the company extend its patent protection. If anyone thinks the dates are wrong, they have until March 30, 2026, to speak up. Also, people can challenge whether the company acted quickly enough during the review by July 27, 2026. This means more time and money could be on the line for the patent holder and competitors.